A Long-Term Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole (OPC 14597) as Maintenance Treatment in Adolescent Patients With Schizophrenia.

Trial Profile

A Long-Term Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole (OPC 14597) as Maintenance Treatment in Adolescent Patients With Schizophrenia.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Apr 2015

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms ATTAIN-266
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 01 Dec 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 May 2013 Planned number of patients changed from 340 to 260 as reported by ClinicalTrials.gov.
    • 07 May 2013 Planned end date changed from 1 Mar 2015 to 1 May 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top